---
title: "After-hours stock price of Novo Nordisk rises by 10% as weight loss oral medication receives FDA approval"
description: "Novo Nordisk's weight loss oral medication has received approval from the U.S. FDA and will compete with Eli Lilly in the weight loss drug market. The drug contains 25 mg of semaglutide, the same ingr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270550940.md"
published_at: "2025-12-23T00:48:18.000Z"
---

# After-hours stock price of Novo Nordisk rises by 10% as weight loss oral medication receives FDA approval

> Novo Nordisk's weight loss oral medication has received approval from the U.S. FDA and will compete with Eli Lilly in the weight loss drug market. The drug contains 25 mg of semaglutide, the same ingredient as Wegovy and Ozempic injections, and is marketed under the Wegovy brand. Following the announcement, Novo Nordisk's stock price rose 10.56% in after-hours trading to $53.18. Research shows that individuals taking the drug lost an average of 16.6%, compared to 2.7% in the placebo group

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk (NVO.US) for an oral weight loss medication, which will compete with rival Eli Lilly (LLY.US) in the weight loss drug market.

The weight loss medication contains 25 mg of semaglutide, the same active ingredient as the injectable Wegovy and Ozempic, and will be marketed under the Wegovy brand name. Following the approval announcement, Novo Nordisk's stock price rose 10.56% in after-hours trading to $53.18.

According to a 64-week late-stage study, individuals taking 25 mg of oral somapraglutide daily lost an average of 16.6%, while participants taking a placebo lost an average of 2.7%

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biocon 計劃通過推出仿製減肥藥來推動收入大幅增長 | Biocon 計劃通過全球推出包括諾和諾德的 Wegovy 和利拉魯肽在內的仿製減肥藥，實現高雙位數的收入增長。該公司計劃在下一個財年在美國推出利拉魯肽，並在加拿大推出 Wegovy，同時由於激烈的價格競爭和監管障礙，對進入印度市場持謹慎態 | [Link](https://longbridge.com/en/news/275900960.md) |
| 諾和諾德公司確認收到 FDA 關於 Wegovy 藥片電視廣告的 “未命名信函” | 諾和諾德公司：確認諾和諾德收到美國食品藥品監督管理局（FDA）關於 WEGOVY 藥丸電視廣告的 “未命名信函” 諾和諾德公司：正在與 FDA 溝通，以解決他們對 WEGOVY 藥丸廣告展示的擔憂諾和諾德公司：確認諾和諾德收到美國食品藥品監 | [Link](https://longbridge.com/en/news/275349213.md) |
| 諾和諾德公司在美國全面推出減肥藥 | 諾和諾德公司在美國推出減肥藥 | [Link](https://longbridge.com/en/news/274912821.md) |
| 諾和諾德公司將在其愛爾蘭工廠生產 Wegovy | 諾和諾德公司將在愛爾蘭工廠生產 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| Berenberg 銀行重申其對諾和諾德公司（0QIU）的買入評級 | Berenberg Bank 分析師 Kerry Holford 重申了對諾和諾德公司 (0QIU) 的買入評級，目標價為 360.00 丹麥克朗。Holford 是一位四星級分析師，成功率為 59.14%，專注於醫療保健領域。最近，德意志 | [Link](https://longbridge.com/en/news/275719942.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.